Self-medication is a human behavior in which an individual uses a substance or any exogenous influence to self-administer treatment for physical or psychological ailments.
The most widely self-medicated substances are over-the-counter drugs and dietary supplements, which are used to treat common health issues at home. These do not require a doctor's prescription to obtain and, in some countries, are available in supermarkets and convenience stores.
The field of psychology surrounding the use of psychoactive drugs is often specifically in relation to the use of recreational drugs, alcohol, comfort food, and other forms of behavior to alleviate symptoms of mental distress, stress and anxiety, including mental illnesses or psychological trauma, is particularly unique and can serve as a serious detriment to physical and mental health if motivated by addictive mechanisms. In postsecondary (university and college) students, the use of self-medicating of study-drugs such as Adderall, Ritalin, and Concerta has been widely reported and discussed in literature.
Products are marketed by manufacturers as useful for self-medication, sometimes on the basis of questionable evidence. Claims that nicotine has medicinal value have been used to market cigarettes as self-administered medicines. These claims have been criticized as inaccurate by independent researchers. Unverified and unregulated third-party health claims are used to market dietary supplements.
Self-medication is often seen as gaining personal independence from established medicine, and it can be seen as a human right, implicit in, or closely related to the right to refuse professional medical treatment. Self-medication can cause unintentional self-harm.
Generally speaking, self-medication is defined as "the use of drugs to treat self-diagnosed disorders or symptoms, or the intermittent or continued use of a prescribed drug for chronic or recurrent disease or symptoms".
Psychology and psychiatry
As different drugs have different effects, they may be used for different reasons. According to the self-medication hypothesis (SMH), the individuals' choice of a particular drug is not accidental or coincidental, but instead, a result of the individuals' psychological condition, as the drug of choice provides relief to the user specific to his or her condition. Specifically, addiction is hypothesized to function as a compensatory means to modulate effects and treat distressful psychological states, whereby individuals choose the drug that will most appropriately manage their specific type of psychiatric distress and help them achieve emotional stability.
The self-medication hypothesis (SMH) originated in papers by Edward Khantzian, Mack and Schatzberg, David F. Duncan, and a response to Khantzian by Duncan. The SMH initially focused on heroin use, but a follow-up paper added cocaine. The SMH was later expanded to include alcohol, and finally all drugs of addiction.
According to Khantzian's view of addiction, drug users compensate for deficient ego function by using a drug as an "ego solvent", which acts on parts of the self that are cut off from consciousness by defense mechanisms. According to Khantzian, drug dependent individuals generally experience more psychiatric distress than non-drug dependent individuals, and the development of drug dependence involves the gradual incorporation of the drug effects and the need to sustain these effects into the defensive structure-building activity of the ego itself. The addict's choice of drug is a result of the interaction between the psychopharmacologic properties of the drug and the affective states from which the addict was seeking relief. The drug's effects substitute for defective or non-existent ego mechanisms of defense. The addict's drug of choice, therefore, is not random.
While Khantzian takes a psychodynamic approach to self-medication, Duncan's model focuses on behavioral factors. Duncan described the nature of positive reinforcement (e.g., the "high feeling", approval from peers), negative reinforcement (e.g. reduction of negative affect) and avoidance of withdrawal symptoms, all of which are seen in those who develop problematic drug use, but are not all found in all recreational drug users. While earlier behavioral formulations of drug dependence using operant conditioning maintained that positive and negative reinforcement were necessary for drug dependence, Duncan maintained that drug dependence was not maintained by positive reinforcement, but rather by negative reinforcement. Duncan applied a public health model to drug dependence, where the agent (the drug of choice) infects the host (the drug user) through a vector (e.g., peers), while the environment supports the disease process, through stressors and lack of support.
Khantzian revisited the SMH, suggesting there is more evidence that psychiatric symptoms, rather than personality styles, lie at the heart of drug use disorders. Khantzian specified that the two crucial aspects of the SMH were that (1) drugs of abuse produce a relief from psychological suffering and (2) the individual's preference for a particular drug is based on its psychopharmacological properties. The individual's drug of choice is determined through experimentation, whereby the interaction of the main effects of the drug, the individual's inner psychological turmoil, and underlying personality traits identify the drug that produces the desired effects.
Meanwhile, Duncan's work focuses on the difference between recreational and problematic drug use. Data obtained in the Epidemiologic Catchment Area Study demonstrated that only 20% of drug users ever experience an episode of drug abuse (Anthony & Helzer, 1991), while data obtained from the National Comorbidity Study demonstrated that only 15% of alcohol users and 15% of illicit drug users ever become dependent. A crucial determinant of whether a drug user develops drug abuse is the presence or absence of negative reinforcement, which is experienced by problematic users, but not by recreational users. According to Duncan, drug dependence is an avoidance behavior, where an individual finds a drug that produces a temporary escape from a problem, and taking the drug is reinforced as an operant behavior.
Some mental illness sufferers attempt to correct their illnesses by using certain drugs. Depression is often self-medicated with alcohol, tobacco, cannabis, or other mind-altering drug use. While this may provide immediate relief of some symptoms such as anxiety, it may evoke and/or exacerbate some symptoms of several kinds of mental illnesses that are already latently present, and may lead to addiction/dependence, among other side effects of long-term use of the drug.
Due to the different effects of the different classes of drugs, the SMH postulates that the appeal of a specific class of drugs differs from person to person. In fact, some drugs may be aversive for individuals for whom the effects could worsen affective deficits.
Alcohol and sedative/hypnotic drugs, such as barbiturates and benzodiazepines, are central nervous system (CNS) depressants that lower inhibitions via anxiolysis. Depressants produce feelings of relaxation and sedation, while relieving feelings of depression and anxiety. Though they are generally ineffective antidepressants, as most are short-acting, the rapid onset of alcohol and sedative/hypnotics softens rigid defenses and, in low to moderate doses, provides relief from depressive affect and anxiety. As alcohol also lowers inhibitions, alcohol is also hypothesized to be used by those who normally constrain emotions by attenuating intense emotions in high or obliterating doses, which allows them to express feelings of affection, aggression and closeness. People with social anxiety disorder commonly use these drugs to overcome their highly set inhibitions.
Psychostimulants, such as cocaine, amphetamines, methylphenidate, caffeine, and nicotine, produce improvements in physical and mental functioning, including increased energy and alertness. Stimulants tend to be most widely used by people suffering from ADHD, which can either be diagnosed or undiagnosed. Because a significant portion of people suffering from ADHD have not been diagnosed they are more prone to using stimulants like caffeine, nicotine or pseudoephedrine to mitigate their symptoms. It's worth noting that the unawareness concerning the effects of illicit substances such as cocaine, methamphetamine or mephedrone can result in self-medication with these drugs by individuals affected with ADHD symptoms. This self medication can effectively prevent them from getting diagnosed with ADHD and receiving treatment with stimulants like methylphenidate and amphetamines.
Stimulants also can be beneficial for individuals who experience depression, to reduce anhedonia and increase self-esteem., however in some cases depression may occur as a comorbid condition originating from the prolonged presence of negative symptoms of undiagnosed ADHD, which can impair executive functions, resulting in lack of motivation, focus and contentment with one's life, so stimulants may be useful for treating treatment-resistant depression, especially in individuals thought to have ADHD. The SMH also hypothesizes that hyperactive and hypomanic individuals use stimulants to maintain their restlessness and heighten euphoria. Additionally, stimulants are useful to individuals with social anxiety by helping individuals break through their inhibitions. Some reviews suggest that students use psychostimulants to self medicate for underlying conditions, such as ADHD, depression or anxiety.
Opiates, such as heroin and morphine, function as an analgesic by binding to opioid receptors in the brain and gastrointestinal tract. This binding reduces the perception of and reaction to pain, while also increasing pain tolerance. Opiates are hypothesized to be used as self-medication for aggression and rage. Opiates are effective anxiolytics, mood stabilizers, and anti-depressants, however, people tend to self-medicate anxiety and depression with depressants and stimulants respectively, though this is by no means an absolute analysis.
Modern research into novel antidepressants targeting opioid receptors suggests that endogenous opioid dysregulation may play a role in medical conditions including anxiety disorders, clinical depression, and borderline personality disorder. BPD is typically characterized by sensitivity to rejection, isolation, and perceived failure, all of which are forms of psychological pain. As research suggests that psychological pain and physiological pain both share the same underlying mechanism, it is likely that under the self-medication hypothesis some or most recreational opioid users are attempting to alleviate psychological pain with opioids in the same way opioids are used to treat physiological pain.
Cannabis is paradoxical in that it simultaneously produces stimulating, sedating and mildly psychedelic properties and both anxiolytic or anxiogenic properties, depending on the individual and circumstances of use. Depressant properties are more obvious in occasional users, and stimulating properties are more common in chronic users. Khantzian noted that research had not sufficiently addressed a theoretical mechanism for cannabis, and therefore did not include it in the SMH.
Self-medicating excessively for prolonged periods of time with benzodiazepines or alcohol often makes the symptoms of anxiety or depression worse. This is believed to occur as a result of the changes in brain chemistry from long-term use. Of those who seek help from mental health services for conditions including anxiety disorders such as panic disorder or social phobia, approximately half have alcohol or benzodiazepine dependence issues.
Sometimes anxiety precedes alcohol or benzodiazepine dependence but the alcohol or benzodiazepine dependence acts to keep the anxiety disorders going, often progressively making them worse. However, some people addicted to alcohol or benzodiazepines, when it is explained to them that they have a choice between ongoing poor mental health or quitting and recovering from their symptoms, decide on quitting alcohol or benzodiazepines or both. It has been noted that every individual has an individual sensitivity level to alcohol or sedative hypnotic drugs, and what one person can tolerate without ill health, may cause another to suffer very ill health, and even moderate drinking can cause rebound anxiety syndrome and sleep disorders. A person suffering the toxic effects of alcohol will not benefit from other therapies or medications, as these do not address the root cause of the symptoms.
Nicotine addiction seems to worsen mental health problems. Nicotine withdrawal depresses mood, increases anxiety and stress, and disrupts sleep. Although nicotine products temporarily relieve their nicotine withdrawal symptoms, an addiction causes stress and mood to be worse on average, due to mild withdrawal symptoms between hits. Nicotine addicts need the nicotine to temporarily feel normal. Nicotine industry marketing has claimed that nicotine is both less harmful and therapeutic for people with mental illness, and is a form of self-medication. This claim has been criticised by independent researchers.
Self medicating is a very common precursor to full addictions and the habitual use of any addictive drug has been demonstrated to greatly increase the risk of addiction to additional substances due to long-term neuronal changes. Addiction to any/every drug of abuse tested so far has been correlated with an enduring reduction in the expression of GLT1 (EAAT2) in the nucleus accumbens and is implicated in the drug-seeking behavior expressed nearly universally across all documented addiction syndromes. This long-term dysregulation of glutamate transmission is associated with an increase in vulnerability to both relapse-events after re-exposure to drug-use triggers as well as an overall increase in the likelihood of developing addiction to other reinforcing drugs. Drugs which help to re-stabilize the glutamate system such as N-acetylcysteine have been proposed for the treatment of addiction to cocaine, nicotine, and alcohol.
Self-medication with regard to antibiotics is reported as being highly prevalent and common in developing nations in Asia, Africa, the Middle East, and South America. While being cited as an important alternative to a formal healthcare system where it may be lacking, self-medication can pose a risk to both the patient and community as a whole. The reasons behind self-medication are unique to each region and can relate to health system, societal, economic, health factors, gender, and age. Risks include allergies, lack of cure, and even death.
Self-medication with antibiotics is commonplace in other countries too such as Greece. Such use is cited as a potential factor in the incidence of certain antibiotic resistant bacterial infections in places like Nigeria.
Also inappropriate use of over-the-counter ibuprofen or other nonsteroidal anti-inflammatory drugs during winter influenza outbreaks can lead to death, e.g. due to haemorrhagic duodenitis induced by ibuprofen, or the consequences of exceeding the recommended doses of paracetamol by combining doses of the generic product with proprietary flu-remedies and Tylex (paracetamol and codeine).
In a questionnaire designed to evaluate self-medication rates amongst the population of Khartoum, Sudan, 48.1% of respondents reported self-medicating with antibiotics within the past 30 days, whereas 43.4% reported self-medicating with antimalarials, and 17.5% reported self-medicating with both. Overall, the total prevalence of reported self-medication with one or both classes of anti-infective agents within the past month was 73.9%. Furthermore, according to the associated study, data indicated that self-medication "varies significantly with a number of socio-economic characteristics" and the "main reason that was indicated for the self-medication was financial constraints".
Physicians and medical students
In a survey of West Bengal, India undergraduate medical school students, 57% reported self-medicating. The type of drugs most frequently used for self-medication were antibiotics (31%), analgesics (23%), antipyretics (18%), antiulcerics (9%), cough suppressants (8%), multivitamins (6%), and anthelmintics (4%).
A study of Luo children in western Kenya found that 19% reported engaging in self-treatment with either herbal or pharmaceutical medicine. Proportionally, boys were much more likely to self-medicate using conventional medicine than herbal medicine as compared with girls, a phenomenon which was theorized to be influenced by their relative earning potential.
Self-medication is highly regulated in much of the world and many classes of drugs are available for administration only upon prescription by licensed medical personnel. Safety, social order, commercialization, and religion have historically been among the prevailing factors that lead to such prohibition.
- Biodiversity and drugs
- Cognitive liberty
- Comfort food
- Dual diagnosis
- Emotional eating
- Psychological trauma
- "What is self-Medication". wsmi.org. WORLD SELF-MEDICATION INDUSTRY. Retrieved 25 May 2016.
- Kirstin Murray (2010-11-10). "Distressed doctors pushed to the limit". Australian Broadcasting Corporation. Retrieved 27 March 2011.
- Vivek Benegal (October 12, 2010). "Addicted to alcohol? Here's why". India Today. Retrieved 27 March 2011.
- Howard Altman (October 10, 2010). "Military suicide rates surge". Tampa Bay Online. Archived from the original on 12 December 2010. Retrieved 27 March 2011.
- Abelman, Dor David (2017-10-06). "Mitigating risks of students use of study drugs through understanding motivations for use and applying harm reduction theory: a literature review". Harm Reduction Journal. 14 (1): 68. doi:10.1186/s12954-017-0194-6. ISSN 1477-7517. PMC 5639593. PMID 28985738.
- Prochaska, Judith J.; Hall, Sharon M.; Bero, Lisa A. (May 2008). "Tobacco Use Among Individuals With Schizophrenia: What Role Has the Tobacco Industry Played?". Schizophrenia Bulletin. 34 (3): 555–567. doi:10.1093/schbul/sbm117. ISSN 0586-7614. PMC 2632440. PMID 17984298.
- Parrott AC (April 2003). "Cigarette-derived nicotine is not a medicine" (PDF). The World Journal of Biological Psychiatry. 4 (2): 49–55. doi:10.3109/15622970309167951. PMID 12692774. S2CID 26903942.
- Reese, Spencer M. "Dietary Supplement Marketing - Rethinking the Use of Third Party Material | MLM Law". www.mlmlaw.com. MLM Law Resources site. Retrieved 14 October 2018.
- Benefits and risks of self-medication
- Three arguments against prescription requirements, Jessica Flanigan, BMJ Group Journal of Medical Ethics 26 July 2012, accessed 20 August 2013
- Kingon, Angus (2012). "Non-prescription medications: considerations for the dental practitioner". Annals of the Royal Australasian College of Dental Surgeons. 21: 88–90. ISSN 0158-1570. PMID 24783837.
- D. Bowen; G. Kisuule; H. Ogasawara; Ch. J. P. Siregar; G. A. Williams; C. Hall; G. Lingam; S. Mann; J. A. Reinstein; M. Couper; J. Idänpään-Heikkilä; J. Yoshida (2000), "Guidelines for the Regulatory Assessment of Medicinal Products for use in Self-Medication" (PDF), WHO/EDM/QSM/00.1, Geneva: World Health Organization, retrieved 2012-09-02
- Awad, Abdelmoneim; Idris Eltayeb; Lloyd Matowe; Lukman Thalib (2005-08-12). "Self-medication with antibiotics and antimalarials in the community of Khartoum State, Sudan". Journal of Pharmacy & Pharmaceutical Sciences. 8 (2): 326–331. PMID 16124943. Retrieved 2012-09-02.
- Khantzian E.J. (1997). "The self-medication hypothesis of drug use disorders: A reconsideration and recent applications". Harvard Review of Psychiatry. 4 (5): 231–244. doi:10.3109/10673229709030550. PMID 9385000. S2CID 39531697.
- Khantzian E.J. (2003). "The self-medication hypothesis revisited: The dually diagnosed patient". Primary Psychiatry. 10: 47–48, 53–54.
- Khantzian, E.J., Mack, J.F., & Schatzberg, A.F. (1974). Heroin use as an attempt to cope: Clinical observations. American Journal of Psychiatry, 131, 160-164.
- Duncan D.F. (1974a). "Reinforcement of drug abuse: Implications for prevention". Clinical Toxicology Bulletin. 4: 69–75.
- Duncan, D.F. (1974b). Letter: Drug abuse as a coping mechanism. American Journal of Psychiatry, 131, 174.
- Khantzian, E.J. (1985). The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. American Journal of Psychiatry, 142, 1259–1264.
- Khantzian, E.J., Halliday, K.S., & McAuliffe, W.E. (1990). Addiction and the vulnerable self: Modified dynamic group therapy for drug abusers. New York: Guilford Press.
- Khantzian, E.J. (1999). Treating addiction as a human process. Northvale, NJ: Jason Aronson.
- Duncan D.F. (1975). "The acquisition, maintenance and treatment of polydrug dependence: A public health model". Journal of Psychedelic Drugs. 7 (2): 209–213. doi:10.1080/02791072.1975.10472000.
- Duncan, D.F., & Gold, R.S. (1983). Cultivating drug use: A strategy for the 80s. Bulletin of the Society of Psychologists in Addictive Behaviors, 2, 143-147. http://www.addictioninfo.org/articles/263/1/Cultivating-Drug-Use/Page1.html
- Anthony, J., Warner, L., & Kessler, R. (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: Basic findings from the National Comorbidity Study. Experimental and Clinical Psychopharmacology, 2, 244-268.
- Nicholson T., Duncan D.F., White J.B. (2002). "Is recreational drug use normal?" (PDF). Journal of Substance Use. 7 (3): 116–123. doi:10.3109/14659890209169340.CS1 maint: multiple names: authors list (link)
- Self-Medication With Alcohol and Drugs by Persons With Severe Mental Illness
- Mental Illness: The Challenge Of Dual Diagnosis Archived 2009-03-08 at the Wayback Machine
- Post Traumatic Stress Disorder
- Sarah W. Book, M.D., and Carrie L. Randall, Ph.D. Social anxiety disorder and alcohol use. Alcohol Research and Health, 2002.
- Bandelow; Schmahl; Falkai; Wedekind (April 2010). "Borderline personality disorder: a dysregulation of the endogenous opioid system?". Psychol. Rev. 117 (2): 623–636. doi:10.1037/a0018095. PMID 20438240.CS1 maint: multiple names: authors list (link)
- Browne; Jacobson; Lucki (February 2020). "Novel Targets to Treat Depression: Opioid-Based Therapeutics". Harv Rev Psychiatry. 28 (1): 40–59. doi:10.1097/HRP.0000000000000242. PMID 31913981.CS1 maint: multiple names: authors list (link)
- Peciña, Marta; Karp, Jordan F; Mathew, Sanjay; Todtenkopf, Mark S; Ehrich, Elliot W; Zubieta, Jon-Kar (April 2019). "Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches". Molecular Psychiatry. 24 (4): 576–587. doi:10.1038/s41380-018-0117-2. PMC 6310672. PMID 29955162.
- Stiglmayr CE, Grathwol T, Linehan MM, Ihorst G, Fahrenberg J, Bohus M (May 2005). "Aversive tension in patients with borderline personality disorder: a computer-based controlled field study". Acta Psychiatr Scand. 111 (5): 372–9. doi:10.1111/j.1600-0447.2004.00466.x. PMID 15819731. S2CID 30951552.
- Eisenberger, NI (2012). "The neural bases of social pain: Evidence for shared representations with physical pain". Psychosomatic Medicine. 74 (2): 126–35. doi:10.1097/PSY.0b013e3182464dd1. PMC 3273616. PMID 22286852.
- Mee, S, Bunney, BG, Reist, C, Potkin, SG, & Bunney, WE. (2006). "Psychological pain: a review of evidence". Journal of Psychiatric Research. 40 (8): 680–90. doi:10.1016/j.jpsychires.2006.03.003. PMID 16725157.CS1 maint: multiple names: authors list (link)
- Eisenberger, Naomi I.; Lieberman, Matthew D. (Jul 2004). "Why rejection hurts: a common neural alarm system for physical and social pain". Trends Cogn Sci. 8 (7): 294–300. doi:10.1016/j.tics.2004.05.010. PMID 15242688. S2CID 15893740.
- Meerwijk, EL, Ford, JM, & Weiss, SJ. (2012). "Brain regions associated with psychological pain: implications for a neural network and its relationship to physical pain". Brain Imaging Behav. 7 (1): 1–14. doi:10.1007/s11682-012-9179-y. PMID 22660945.CS1 maint: multiple names: authors list (link)
- Professor C Heather Ashton (1987). "Benzodiazepine Withdrawal: Outcome in 50 Patients". British Journal of Addiction. 82: 655–671.
- Michelini S; Cassano GB; Frare F; Perugi G (July 1996). "Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders". Pharmacopsychiatry. 29 (4): 127–34. doi:10.1055/s-2007-979558. PMID 8858711.
- Wetterling T; Junghanns K (Dec 2000). "Psychopathology of alcoholics during withdrawal and early abstinence". Eur Psychiatry. 15 (8): 483–8. doi:10.1016/S0924-9338(00)00519-8. PMID 11175926. S2CID 24094651.
- Cowley DS (Jan 1, 1992). "Alcohol abuse, substance abuse, and panic disorder". Am J Med. 92 (1A): 41S–8S. doi:10.1016/0002-9343(92)90136-Y. PMID 1346485.
- Cosci F; Schruers KR; Abrams K; Griez EJ (Jun 2007). "Alcohol use disorders and panic disorder: a review of the evidence of a direct relationship". J Clin Psychiatry. 68 (6): 874–80. doi:10.4088/JCP.v68n0608. PMID 17592911.
- Cohen SI (February 1995). "Alcohol and benzodiazepines generate anxiety, panic and phobias". J R Soc Med. 88 (2): 73–7. PMC 1295099. PMID 7769598.
- Parrott AC (March 2006). "Nicotine psychobiology: how chronic-dose prospective studies can illuminate some of the theoretical issues from acute-dose research". Psychopharmacology. 184 (3–4): 567–76. doi:10.1007/s00213-005-0294-y. PMID 16463194. S2CID 11356233.
- McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM (2014). "Potential role of N-acetylcysteine in the management of substance use disorders". CNS Drugs. 28 (2): 95–106. doi:10.1007/s40263-014-0142-x. PMC 4009342. PMID 24442756.
- Ocan, M; Obuku, EA; Bwanga, F; Akena, D; Richard, S; Ogwal-Okeng, J; Obua, C (1 August 2015). "Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries". BMC Public Health. 15: 742. doi:10.1186/s12889-015-2109-3. PMC 4522083. PMID 26231758.
- Skliros, Eystathios; Panagiotis Merkouris; Athanasia Papazafiropoulou; Aristofanis Gikas; George Matzouranis; Christos Papafragos; Ioannis Tsakanikas; Irene Zarbala; Alexios Vasibosis; Petroula Stamataki; Alexios Sotiropoulos (2010-08-08). "Self-medication with antibiotics in rural population in Greece: a cross-sectional multicenter study". BMC Family Practice. 11 (58): 58. doi:10.1186/1471-2296-11-58. PMC 2924846. PMID 20691111.
- Sapkota, Amy R.; Morenike E. Coker; Rachel E. Rosenberg Goldstein; Nancy L. Atkinson; Shauna J. Sweet; Priscilla O. Sopeju; Modupe T. Ojo; Elizabeth Otivhia; Olayemi O. Ayepola; Olufunmiso O. Olajuyigbe; Laura Shireman; Paul S. Pottinger; Kayode K. Ojo (2010-10-15). "Self-medication with antibiotics for the treatment of menstrual symptoms in southwest Nigeria: a cross-sectional study". BMC Public Health. 10 (610): 610. doi:10.1186/1471-2458-10-610. PMC 2965722. PMID 20946686.
- Stevenson, R; MacWalter, R; Harmse, J (1 June 2001). "Mortality during the winter flu epidemic--two cases of death associated with self-medication". Scottish Medical Journal. 46 (3): 84–86. doi:10.1177/003693300104600307. PMID 11501327. S2CID 30009395.
- Pan, Hui; Binglin Cui; Dangui Zhang; Jeremy Farrar; Frieda Law; William Ba-Thein (2012-07-20). Fielding, Richard (ed.). "Prior Knowledge, Older Age, and Higher Allowance Are Risk Factors for Self-Medication with Antibiotics among University Students in Southern China". PLOS ONE. 7 (7): e41314. Bibcode:2012PLoSO...741314P. doi:10.1371/journal.pone.0041314. PMC 3401104. PMID 22911779.
- Banerjee, I.; T. Bhadury (April–June 2012). "Self-medication practice among undergraduate medical students in a tertiary care medical college, West Bengal". Journal of Postgraduate Medicine. 58 (2): 127–131. doi:10.4103/0022-3859.97175. ISSN 0972-2823. PMID 22718057.
- Nalini, G. K. (2010). "Self-Medication among Allopathic medical Doctors in Karnataka, India". British Journal of Medical Practitioners. 3 (2). Retrieved 2012-09-02.
- Geissler, P.W .; K. Nokes; R. J. Prince; R. Achieng Odhiambo; J. Aagaard-Hansen; J. H. Ouma (June 2000). "Children and medicines: self-treatment of common illnesses among Luo school children in western Kenya". Social Science & Medicine. 50 (12): 1771–1783. doi:10.1016/S0277-9536(99)00428-1. hdl:11295/80905. PMID 10798331.
- Jain, Sonam; Reetesh Malvi; Jeetendra Kumar Purviya (2011). "Concept of Self Medication: A Review" (PDF). International Journal of Pharmaceutical & Biological Archives. 2 (3): 831–836.